Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business Update
Aug 17, 2021
Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)
Aug 12, 2021
Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Aug 5, 2021
Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules
Jul 7, 2021
Tenax Therapeutics Set to Join Russell Microcap® Index
Jun 10, 2021
Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update
May 17, 2021
Tenax Announces Publication Titled “Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial ”
Apr 9, 2021
Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual Meeting of Stockholders
Apr 7, 2021
Tenax Therapeutics Reports Fiscal Year 2020 Results and Provides Business Update
Mar 31, 2021
Tenax Therapeutics to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
Mar 4, 2021